JPWO2022055791A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022055791A5 JPWO2022055791A5 JP2023514417A JP2023514417A JPWO2022055791A5 JP WO2022055791 A5 JPWO2022055791 A5 JP WO2022055791A5 JP 2023514417 A JP2023514417 A JP 2023514417A JP 2023514417 A JP2023514417 A JP 2023514417A JP WO2022055791 A5 JPWO2022055791 A5 JP WO2022055791A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- raav
- administration
- cell
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075697P | 2020-09-08 | 2020-09-08 | |
| US63/075,697 | 2020-09-08 | ||
| PCT/US2021/048957 WO2022055791A1 (en) | 2020-09-08 | 2021-09-03 | Systemic delivery of adeno-associated virus vector expressing g-sarcoglycan and the treatment of muscular dystrophy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540095A JP2023540095A (ja) | 2023-09-21 |
| JP2023540095A5 JP2023540095A5 (https=) | 2024-09-11 |
| JPWO2022055791A5 true JPWO2022055791A5 (https=) | 2024-09-11 |
Family
ID=78086895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514417A Pending JP2023540095A (ja) | 2020-09-08 | 2021-09-03 | Ｇ－サルコグリカンを発現するアデノ随伴ウイルスベクターの全身送達および筋ジストロフィーの治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11925675B2 (https=) |
| EP (1) | EP4204088A1 (https=) |
| JP (1) | JP2023540095A (https=) |
| KR (1) | KR20230066021A (https=) |
| CN (1) | CN116134047A (https=) |
| AR (1) | AR123445A1 (https=) |
| AU (1) | AU2021340584A1 (https=) |
| BR (1) | BR112023003736A2 (https=) |
| CA (1) | CA3189647A1 (https=) |
| CO (1) | CO2023004031A2 (https=) |
| IL (1) | IL300986A (https=) |
| MX (1) | MX2023002569A (https=) |
| TW (2) | TW202541851A (https=) |
| WO (1) | WO2022055791A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3005633C (en) | 2015-11-16 | 2023-11-21 | Research Institute Of Nationwide Children's Hospital | Materials and methods for treatment of titin-based myopathies and other titinopathies |
| WO2025171086A1 (en) * | 2024-02-07 | 2025-08-14 | Asimov Inc. | Promoters and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| PT733103E (pt) | 1993-11-09 | 2004-07-30 | Targeted Genetics Corp | Criacao de elevados titulos de vectores de aav recombinantes |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| US5658785A (en) | 1994-06-06 | 1997-08-19 | Children's Hospital, Inc. | Adeno-associated virus materials and methods |
| US5856152A (en) | 1994-10-28 | 1999-01-05 | The Trustees Of The University Of Pennsylvania | Hybrid adenovirus-AAV vector and methods of use therefor |
| AU707866B2 (en) | 1994-12-06 | 1999-07-22 | Targeted Genetics Corporation | Packaging cell lines for generation of high titers of recombinant AAV vectors |
| FR2737730B1 (fr) | 1995-08-10 | 1997-09-05 | Pasteur Merieux Serums Vacc | Procede de purification de virus par chromatographie |
| AU722196B2 (en) | 1995-08-30 | 2000-07-27 | Genzyme Corporation | Chromatographic purification of adenovirus and AAV |
| EP1983057A3 (en) | 1995-09-08 | 2009-01-07 | Genzyme Corporation | Improved AAV vectors for gene therapy |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| EP0932418B1 (en) | 1996-09-06 | 2007-12-05 | The Trustees Of The University Of Pennsylvania | Method for recombinant adeno-associated virus-directed gene therapy |
| JP2001514845A (ja) | 1997-09-05 | 2001-09-18 | ターゲティッド ジェネティクス コーポレイション | 組換えａａｖベクターの高力価ヘルパーなし調製物を生成するための方法 |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6258595B1 (en) | 1999-03-18 | 2001-07-10 | The Trustees Of The University Of Pennsylvania | Compositions and methods for helper-free production of recombinant adeno-associated viruses |
| CA2406743A1 (en) | 2000-04-28 | 2001-11-08 | The Trustees Of The University Of Pennsylvania | Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids |
| AU2002248297A1 (en) | 2001-01-05 | 2002-07-16 | Children's Hospital, Inc. | Aav2 vectors and methods |
| DE102012007232B4 (de) | 2012-04-07 | 2014-03-13 | Susanne Weller | Verfahren zur Herstellung von rotierenden elektrischen Maschinen |
| JP2015092462A (ja) | 2013-09-30 | 2015-05-14 | Tdk株式会社 | 正極及びそれを用いたリチウムイオン二次電池 |
| JP6202701B2 (ja) | 2014-03-21 | 2017-09-27 | 株式会社日立国際電気 | 基板処理装置、半導体装置の製造方法及びプログラム |
| JP6197169B2 (ja) | 2014-09-29 | 2017-09-20 | 東芝メモリ株式会社 | 半導体装置の製造方法 |
| MX2020007876A (es) * | 2018-01-31 | 2020-12-03 | Res Inst Nationwide Childrens Hospital | Terapia genica para la distrofia muscular de cinturas tipo 2c. |
| MX2021010356A (es) * | 2019-02-26 | 2022-03-04 | Res Inst Nationwide Childrens Hospital | SUMINISTRO DE ß-SARCOGLICANO MEDIANTE VECTORES DE VIRUS ADENOASOCIADO Y EL TRATAMIENTO DE LA DISTROFIA MUSCULAR. |
| JP7847084B2 (ja) * | 2019-12-16 | 2026-04-16 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | ジストロフィン関連タンパク質複合体（ｄａｐｃ）を回復および維持するための組成物および方法 |
| US20230256117A1 (en) * | 2020-06-19 | 2023-08-17 | Genethon | Gene therapy expression system allowing an adequate expression in the muscles and in the heart of sgcg |
-
2021
- 2021-08-30 TW TW114126376A patent/TW202541851A/zh unknown
- 2021-08-30 TW TW110132144A patent/TWI887479B/zh active
- 2021-09-03 AU AU2021340584A patent/AU2021340584A1/en active Pending
- 2021-09-03 BR BR112023003736A patent/BR112023003736A2/pt unknown
- 2021-09-03 MX MX2023002569A patent/MX2023002569A/es unknown
- 2021-09-03 KR KR1020237011162A patent/KR20230066021A/ko active Pending
- 2021-09-03 CN CN202180053937.3A patent/CN116134047A/zh active Pending
- 2021-09-03 EP EP21790297.2A patent/EP4204088A1/en active Pending
- 2021-09-03 WO PCT/US2021/048957 patent/WO2022055791A1/en not_active Ceased
- 2021-09-03 JP JP2023514417A patent/JP2023540095A/ja active Pending
- 2021-09-03 IL IL300986A patent/IL300986A/en unknown
- 2021-09-03 CA CA3189647A patent/CA3189647A1/en active Pending
- 2021-09-07 US US17/468,086 patent/US11925675B2/en active Active
- 2021-09-07 AR ARP210102484A patent/AR123445A1/es unknown
-
2023
- 2023-03-29 CO CONC2023/0004031A patent/CO2023004031A2/es unknown
-
2024
- 2024-02-16 US US18/444,018 patent/US20240374684A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250059532A1 (en) | Modified Guide RNAs | |
| US20250049954A1 (en) | Stable compositions of mrna-loaded lipid nanoparticles and processes of making | |
| JP7448488B2 (ja) | メッセンジャーｒｎａの皮下送達 | |
| GB2590880A (en) | RNA and DNA base editing via engineered ADAR recruitment | |
| US8927514B2 (en) | Recombinant adeno-associated vectors for targeted treatment | |
| ES2230502T3 (es) | Disolucion tampon para la electroporacion y procedimiento que incluye el uso de la misma. | |
| US20180236103A1 (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| US20170211094A1 (en) | Recombinant adeno-associated vectors for targeted treatment | |
| UA119140C2 (uk) | Мутеїн інтерлейкіну-2, що стимулює регуляторні t-клітини | |
| WO2018195555A1 (en) | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors | |
| CN111117985B (zh) | 一种拆分Cas9的方法及其应用 | |
| JP2024133657A5 (https=) | ||
| US6989374B1 (en) | Gene therapy for cardiomyopathy | |
| US20220347112A1 (en) | Compositions and methods for delivery of rna | |
| EP4150079A1 (en) | Messenger rna encoding cas9 for use in genome-editing systems | |
| JP2025537601A (ja) | 組換えアデノ随伴ウイルスベクターの薬学的組成物及びその適用 | |
| JP3304932B2 (ja) | 共有結合で閉鎖された環状ｄｎａを精製するための新規な方法 | |
| JP2023505522A (ja) | Ｎａｄｈデヒドロゲナーゼタンパク質でレーベル遺伝性視神経症を治療するための組成物及び方法 | |
| JPWO2020176614A5 (https=) | ||
| JPWO2022055791A5 (https=) | ||
| JPWO2020223362A5 (https=) | ||
| US6387695B1 (en) | DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof | |
| BR112019017444A2 (pt) | regulação da expressão gênica por acessibilidade mediada por aptâmero de sinais de poliadenilação | |
| JP2024542023A (ja) | ファブリー病の治療のためのウイルスベクター構築物の使用方法 | |
| US20250269062A1 (en) | Methods for in vivo editing of a liver gene |